1/14
08:42 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
1/10
07:02 pm
phat
Should Phathom's US$130 Million Equity Raise and Profitability Timeline Update Require Action From Phathom Pharmaceuticals (PHAT) Investors? [Yahoo! Finance]
Medium
Report
Should Phathom's US$130 Million Equity Raise and Profitability Timeline Update Require Action From Phathom Pharmaceuticals (PHAT) Investors? [Yahoo! Finance]
1/9
07:25 pm
phat
Phathom: Why I'm Not Buying The Dip (Yet) [Seeking Alpha]
Medium
Report
Phathom: Why I'm Not Buying The Dip (Yet) [Seeking Alpha]
1/7
10:33 pm
phat
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
1/7
04:05 pm
phat
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
1/7
04:01 pm
phat
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
High
Report
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
12/13
07:50 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
12/11
05:04 pm
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
12/11
06:29 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Barclays PLC to a "hold" rating.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Barclays PLC to a "hold" rating.
12/8
06:06 pm
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) was given a new $16.00 price target on by analysts at Barclays PLC.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) was given a new $16.00 price target on by analysts at Barclays PLC.
11/21
04:07 pm
phat
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth [Seeking Alpha]
Low
Report
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth [Seeking Alpha]
11/13
12:02 am
phat
Could Clinical Progress With VOQUEZNA Reshape Phathom Pharmaceuticals' Long-Term Strategy (PHAT)? [Yahoo! Finance]
Low
Report
Could Clinical Progress With VOQUEZNA Reshape Phathom Pharmaceuticals' Long-Term Strategy (PHAT)? [Yahoo! Finance]
11/4
08:00 am
phat
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Low
Report
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
11/3
07:59 am
phat
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
10/31
10:07 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Craig Hallum.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Craig Hallum.
10/31
07:19 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/30
06:06 pm
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Guggenheim.
10/30
07:00 am
phat
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
10/25
10:10 am
phat
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease [Yahoo! Finance]
Low
Report
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease [Yahoo! Finance]
10/25
09:59 am
phat
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
Low
Report
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
10/23
08:00 am
phat
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
Low
Report
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting